000275876 001__ 275876
000275876 005__ 20250126000507.0
000275876 0247_ $$2doi$$a10.1002/brb3.70248
000275876 0247_ $$2pmid$$apmid:39779216
000275876 0247_ $$2pmc$$apmc:PMC11710889
000275876 0247_ $$2altmetric$$aaltmetric:172896152
000275876 037__ $$aDZNE-2025-00111
000275876 041__ $$aEnglish
000275876 082__ $$a610
000275876 1001_ $$00000-0001-8153-3025$$aOlma, Manuel C$$b0
000275876 245__ $$aThe Role of Atrial Fibrillation and Oral Anticoagulation Status in Health-Related Quality of Life 12 Months After Ischemic Stroke or TIA.
000275876 260__ $$aMalden, Mass.$$bWiley$$c2025
000275876 3367_ $$2DRIVER$$aarticle
000275876 3367_ $$2DataCite$$aOutput Types/Journal article
000275876 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737365399_4997
000275876 3367_ $$2BibTeX$$aARTICLE
000275876 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275876 3367_ $$00$$2EndNote$$aJournal Article
000275876 520__ $$aAtrial fibrillation (AF) accounts for about 20% of all ischemic strokes worldwide. It is known that AF impairs health-related quality of life (HRQOL) in the general population, but data on HRQOL in stroke patients with newly diagnosed AF are sparse.Post hoc analysis of the prospective, investigator-initiated, multicenter MonDAFIS study (NCT02204267) to analyze whether AF-related oral anticoagulation (OAC), and/or AF-symptom severity are associated with HRQOL after ischemic stroke or transient ischemic attack (TIA). HRQOL was measured using the EQ-5D-3L-questionnaire (including EQ-index/EQ-VAS) at baseline and after 12 months using multivariable linear mixed models. AF symptom severity was assessed using the European Heart Rhythm Association classification and symptom severity score (EHRA score) categorizing patients with no/mild/severe/disabling AF-related symptoms.A first episode of AF was detected in 261/2927 (8.9%) patients within 12 months after the index stroke and 227/2920 (7.8%) patients had AF and were anticoagulated at 12 months. HRQOL (measured by EQ-index, n = 2495 patients) was higher in AF patients on OAC compared to AF patients without OAC at 12 months after stroke (mean difference: MD: -16.8, 95% CI: 5.6 to 28.0), and similar in AF patients under OAC compared with patients without AF (MD: 2.0, 95% CI: -2.2 to 6.3). AF-related symptoms were negatively associated with HRQOL (measured by EQ-index) indicating that stroke patients with AF-related symptoms had a lower HRQOL compared to asymptomatic AF patients (mild vs. asymptomatic: MD: -9.0, 95% CI: -17.7 to -0.3; severe/disabling vs. asymptomatic: MD: -19.1, 95% CI: -34.7 to -3.4).Stroke patients with newly diagnosed AF are at risk of lower quality of life at 12 months, depending on OAC status and AF symptom severity.
000275876 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000275876 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000275876 650_7 $$2Other$$aatrial fibrillation
000275876 650_7 $$2Other$$aischemic stroke
000275876 650_7 $$2Other$$aoral anticoagulation
000275876 650_7 $$2Other$$aquality of life
000275876 650_7 $$2Other$$atransient ischemic attack
000275876 650_7 $$2NLM Chemicals$$aAnticoagulants
000275876 650_2 $$2MeSH$$aHumans
000275876 650_2 $$2MeSH$$aAtrial Fibrillation: drug therapy
000275876 650_2 $$2MeSH$$aAtrial Fibrillation: physiopathology
000275876 650_2 $$2MeSH$$aAtrial Fibrillation: complications
000275876 650_2 $$2MeSH$$aQuality of Life
000275876 650_2 $$2MeSH$$aFemale
000275876 650_2 $$2MeSH$$aMale
000275876 650_2 $$2MeSH$$aAnticoagulants: administration & dosage
000275876 650_2 $$2MeSH$$aAged
000275876 650_2 $$2MeSH$$aIschemic Stroke: physiopathology
000275876 650_2 $$2MeSH$$aIschemic Attack, Transient: physiopathology
000275876 650_2 $$2MeSH$$aMiddle Aged
000275876 650_2 $$2MeSH$$aProspective Studies
000275876 650_2 $$2MeSH$$aAged, 80 and over
000275876 650_2 $$2MeSH$$aAdministration, Oral
000275876 650_2 $$2MeSH$$aSeverity of Illness Index
000275876 7001_ $$aSteindorf-Sabath, Lena$$b1
000275876 7001_ $$00000-0002-5057-7487$$aTütüncü, Serdar$$b2
000275876 7001_ $$aKunze, Claudia$$b3
000275876 7001_ $$aFiessler, Cornelia$$b4
000275876 7001_ $$aKirchhof, Paulus$$b5
000275876 7001_ $$aDietzel, Joanna$$b6
000275876 7001_ $$aSchurig, Johannes$$b7
000275876 7001_ $$aOschmann, Patrick$$b8
000275876 7001_ $$aNiehaus, Ludwig$$b9
000275876 7001_ $$aUrbanek, Christian$$b10
000275876 7001_ $$aThomalla, Götz$$b11
000275876 7001_ $$aNabavi, Darius G$$b12
000275876 7001_ $$aRöther, Joachim$$b13
000275876 7001_ $$aLaufs, Ulrich$$b14
000275876 7001_ $$aVeltkamp, Roland$$b15
000275876 7001_ $$aHeuschmann, Peter U$$b16
000275876 7001_ $$aHaeusler, Karl Georg$$b17
000275876 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b18$$eLast author$$udzne
000275876 7001_ $$aInvestigators, MonDAFIS$$b19$$eCollaboration Author
000275876 773__ $$0PERI:(DE-600)2623587-0$$a10.1002/brb3.70248$$gVol. 15, no. 1, p. e70248$$n1$$pe70248$$tBrain and behavior$$v15$$x2162-3279$$y2025
000275876 8564_ $$uhttps://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.docx
000275876 8564_ $$uhttps://pub.dzne.de/record/275876/files/DZNE-2025-00111.pdf$$yOpenAccess
000275876 8564_ $$uhttps://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.doc
000275876 8564_ $$uhttps://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.odt
000275876 8564_ $$uhttps://pub.dzne.de/record/275876/files/DZNE-2025-00111%20SUP.pdf
000275876 8564_ $$uhttps://pub.dzne.de/record/275876/files/DZNE-2025-00111.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000275876 909CO $$ooai:pub.dzne.de:275876$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000275876 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000275876 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000275876 9141_ $$y2025
000275876 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-06
000275876 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000275876 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN BEHAV : 2022$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-06$$wger
000275876 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:05:29Z
000275876 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:05:29Z
000275876 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000275876 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-06
000275876 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-06
000275876 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000275876 980__ $$ajournal
000275876 980__ $$aVDB
000275876 980__ $$aUNRESTRICTED
000275876 980__ $$aI:(DE-2719)1811005
000275876 9801_ $$aFullTexts